Chronoscale Holdings Corp quarterly report, Q3 FY2017

Ekso Bionics Holdings, Inc. — Form 10-Q Summary

Issuer discrepancy: The request metadata names Chronoscale Holdings Corp., but the filing is for Ekso Bionics Holdings, Inc. (Nasdaq: EKSO). The filing covers the quarter and nine months ended September 30, 2017; financial statements are unaudited. Amounts below are USD millions unless stated otherwise.

Business context and reporting period

Ekso develops wearable exoskeletons for medical rehabilitation, industrial use, and engineering services. Management said it was prioritizing commercialization of the Ekso GT rehabilitation device and exploring strategic alternatives to accelerate adoption of industrial products. The company reported three segments: Medical Devices, Industrial Sales, and Engineering Services.

Financial performance and liquidity

MetricQ3 2017Q3 2016Nine months 2017Nine months 2016
Revenue$1.597$1.596$4.900$11.634
Gross profit (margin)$0.544 (34.1%)$0.403 (25.3%)$1.292 (26.4%)$2.104 (18.1%)
Operating loss$(7.066)$(6.866)$(23.666)$(20.904)
Net loss$(6.335)$(8.478)$(20.144)$(17.894)
Net loss per share, basic$(0.18)$(0.60)$(0.73)$(1.67)
  • Q3 device-and-related revenue rose 6%; engineering-services revenue fell to $0.010 million from $0.101 million. Q3 gross profit improved, while operating loss widened as operating expenses increased 5% to $7.610 million.
  • Nine-month revenue fell 58%, primarily because 2016 included $6.5 million of revenue recognized following a change in revenue-recognition estimates, and because engineering-services work was lower. Nine-month gross profit declined 39%.
  • Nine-month operating expenses increased 8% to $24.958 million; sales and marketing and R&D expenses increased, while G&A declined. The operating loss widened 13%. The reported net loss was also higher year over year; 2016 included a $10.345 million preferred deemed dividend, so net loss applicable to common stockholders improved to $(20.144) million from $(28.239) million.
  • Cash was $33.439 million at September 30, 2017, versus $16.846 million at December 31, 2016. Current assets were $40.168 million and current liabilities $6.592 million. Working capital was approximately $33.576 million.
  • Cash used in operating activities was $25.582 million for the first nine months, versus $20.555 million in 2016. Investing used $0.353 million; financing provided $42.459 million, principally from equity offerings.
  • Debt was reported at a net carrying amount of $6.924 million, including $1.556 million current and $5.368 million non-current. The term loan bears interest at 30-day LIBOR plus 5.41%, is secured by substantially all assets except intellectual property, and matures in 2021. The company reported compliance with its liquidity and other loan covenants at quarter-end.

Material changes, outlook, and risks

  • Capital and dilution: An April registered direct offering generated approximately $10.9 million net. The August rights offering and related backstop private placement issued about 34.0 million shares in total; the rights offering provided $13.2 million net and the backstop investor paid $20.5 million. Common shares outstanding were 59,903,876 as of November 1, 2017.
  • Restructuring: In May, the company reduced its workforce by approximately 27 employees. The plan was completed by the end of Q2 and resulted in $0.665 million of nine-month restructuring expense.
  • Management outlook: Management said quarter-end cash was sufficient to fund operations beyond one year from the financial statements’ issuance date. It also said future capital needs could be significant and additional financing may be required; availability and terms are not assured. No quantitative revenue or earnings guidance is provided.
  • Commercial and execution risks: Management cited uncertain customer adoption, long and variable sales cycles, competition and technology changes, clinical-trial timing and outcomes, regulatory approvals, reimbursement, intellectual-property protection, and the need for financing. The company is investing in clinical, sales, marketing, product development, and potential home-use and industrial products.
  • Unusual and non-cash items: Nine-month results included a $4.851 million gain from revaluation of warrant liabilities and a $1.067 million loss on repurchasing April 2017 warrants. Warrant revaluation gains and losses are driven largely by share-price movements and are not a measure of operating performance. The April warrants were repurchased in connection with the rights offering.
  • Related party: Puissance Capital, whose affiliate’s founder joined the board, acquired about 20.535 million shares in the backstop placement and held approximately 34% of shares after the offering. The company also paid an affiliated consulting firm $2.150 million in Q3 for a one-year strategic-positioning engagement, with the fees expensed over the contract term.
  • Other disclosures: The filing says management considered the prior-year going-concern substantial doubt alleviated by 2017 actions, but continued losses and operating cash burn leave financing and execution risks. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

  • Confirm the intended issuer: the supplied filing is Ekso Bionics Holdings, Inc., not Chronoscale Holdings Corp.
  • Assess cash runway against the $25.582 million nine-month operating cash outflow and management’s stated expectation of possible future financing needs.
  • Review the revenue comparison in light of the $6.5 million 2016 recognition effect, and distinguish underlying sales trends from accounting and warrant-valuation effects.
  • Verify the full dilution and ownership consequences of the offerings, warrants, and Puissance-related transactions, including the consulting arrangement and board relationship.
  • Monitor Ekso GT adoption, industrial product sales, clinical evidence, regulatory status, and whether the company can reduce cash burn while expanding commercialization.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.